Find Lafutidine manufacturers, exporters & distributors on PharmaCompass

Lafutidine

Lafutidine

Synopsis, Chemistry

APIs // Active Pharmaceutical Ingredients

11 API Suppliers, 5 JDMF, 10 KDMF, 6 Listed Suppliers

PRICE INFORMATION

API Reference Price, API Exports

INTERMEDIATES

4 Suppliers

4 Suppliers

DOSSIERs // Finished Dosage Formulations

2 Dossiers, 2 Listed Dossiers

MARKET PLACE

7 APIs

7 APIs

DIGITAL CONTENT

2 News

2 News

Product Search

API SUPPLIERS

API Suppliers

US DMFs Filed

CEP/COS Certifications

JDMFs Filed

EU WC

Listed Suppliers

API REF. PRICE (USD / KG)

1,324

API Market Place

INTERMEDIATES

DOSSIERS // FDF

USA (Orange Book)

Europe

Canada

Australia

South Africa

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

FDF Market Place

EXCIPIENTS

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

USP

Other Listed Suppliers

SERVICES

Also known as: 118288-08-7, 206449-93-6, Frg-8813, Lafutidine [inn], (z)-lafutidine, Lafutidine [jan]

Molecular Formula

C₂₂H₂₉N₃O₄S

Molecular Weight

431.6 g/mol

InChI Key

KMZQAVXSMUKBPD-DJWKRKHSSA-N

FDA UNII

49S4O7ADLC

Lafutidine has been investigated in Peptic Ulcer, Community-acquired Pneumonia, and Gastroesophageal Reflux Disease (GERD).

1 2D Structure

Lafutidine

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

2-(furan-2-ylmethylsulfinyl)-N-[(Z)-4-[4-(piperidin-1-ylmethyl)pyridin-2-yl]oxybut-2-enyl]acetamide

2.1.2 InChI

InChI=1S/C22H29N3O4S/c26-21(18-30(27)17-20-7-6-14-28-20)23-9-2-5-13-29-22-15-19(8-10-24-22)16-25-11-3-1-4-12-25/h2,5-8,10,14-15H,1,3-4,9,11-13,16-18H2,(H,23,26)/b5-2-

2.1.3 InChI Key

KMZQAVXSMUKBPD-DJWKRKHSSA-N

2.1.4 Canonical SMILES

C1CCN(CC1)CC2=CC(=NC=C2)OCC=CCNC(=O)CS(=O)CC3=CC=CO3

2.1.5 Isomeric SMILES

C1CCN(CC1)CC2=CC(=NC=C2)OC/C=C\CNC(=O)CS(=O)CC3=CC=CO3

2.2 Other Identifiers

2.2.1 UNII

49S4O7ADLC

2.3 Synonyms

2.3.1 MeSH Synonyms

1. Frg 8813

2. Frg-8813

3. N-(4-(4-piperidinylmethyl)pyridyl-2-oxy)-(z)-butenyl-2-(furfurylsulfinyl)acetamide

4. N-(4-(4-piperidinylmethyl)pyridyl-2-oxy)butenyl-2-(furfurylsulfinyl)acetamide

2.3.2 Depositor-Supplied Synonyms

1. 118288-08-7

2. 206449-93-6

3. Frg-8813

4. Lafutidine [inn]

5. (z)-lafutidine

6. Lafutidine [jan]

7. Lafutidine Free Base

8. Rac Lafutidine

9. Lafutidine [mart.]

10. Lafutidine [who-dd]

11. Lafutidine, (+/-)-

12. (z)-2-((furan-2-ylmethyl)sulfinyl)-n-(4-((4-(piperidin-1-ylmethyl)pyridin-2-yl)oxy)but-2-en-1-yl)acetamide

13. 49s4o7adlc

14. 118288-08-7 (free Base)

15. 2-(furan-2-ylmethylsulfinyl)-n-[(z)-4-[4-(piperidin-1-ylmethyl)pyridin-2-yl]oxybut-2-enyl]acetamide

16. Acetamide, 2-[(2-furanylmethyl)sulfinyl]-n-[(2z)-4-[[4-(1-piperidinylmethyl)-2-pyridinyl]oxy]-2-buten-1-yl]-

17. Unii-49s4o7adlc

18. Dsstox_cid_26434

19. Dsstox_rid_81611

20. Dsstox_gsid_46434

21. Protecadin

22. (+/-)-2-(furfurylsulfinyl)-n-((z)-4-((4-(piperidinomethyl)-2-pyridyl)oxy)-2-butenyl) Acetamide

23. Cas-118288-08-7

24. Frg 8813

25. Laftidine

26. Stogar

27. Protecadin (tn)

28. Ncgc00164550-01

29. N-(4-(4-piperidinylmethyl)pyridyl-2-oxy)butenyl-2-(furfurylsulfinyl)acetamide

30. Starbld0049801

31. Lafutidine (jp17/inn)

32. Mls006011259

33. Schembl362540

34. Chembl1742461

35. Dtxsid0046434

36. Lafutidine, >=98% (hplc)

37. Chebi:31759

38. Hms3884d03

39. Act06288

40. Hy-b0160

41. Tox21_112179

42. Mfcd21607521

43. S2065

44. Akos005146275

45. Tox21_112179_1

46. Ccg-269024

47. Cs-1992

48. Db12770

49. (+-)-2-(furfurylsulfinyl)-n-(4-(4-(piperidinomethyl)-2-pyridyl)oxy-(z)-2-butenyl)acetamide

50. Ncgc00263530-01

51. (+-)-2-(furfurylsulfinyl)-n-((z)-4-((4-(piperidinomethyl)-2-pyridyl)oxy)-2-butenyl) Acetamide

52. Ac-23354

53. Acetamide, 2-((2-furanylmethyl)sulfinyl)-n-(4-((4-(1-piperidinylmethyl)-2-pyridinyl)oxy)-2-butenyl)-, (z)-

54. Smr002529578

55. L0341

56. Sw219706-1

57. D01131

58. F77861

59. Ab01565815_02

60. 288l087

61. L001355

62. Q582556

63. J-521629

64. F0001-2391

2.4 Create Date

2005-06-24

3 Chemical and Physical Properties

Molecular Formula	C₂₂H₂₉N₃O₄S
Molecular Weight	431.6 g/mol
XLogP3	1.4
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	7
Rotatable Bond Count	11
Exact Mass	431.18787759 g/mol
Monoisotopic Mass	431.18787759 g/mol
Topological Polar Surface Area	104 Å²
Heavy Atom Count	30
Formal Charge	0
Complexity	569
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	1
Defined Bond Stereocenter Count	1
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Pharmacology and Biochemistry

4.1 MeSH Pharmacological Classification

Anti-Ulcer Agents

Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. (See all compounds classified as Anti-Ulcer Agents.)

Histamine H2 Antagonists

Drugs that selectively bind to but do not activate histamine H2 receptors, thereby blocking the actions of histamine. Their clinically most important action is the inhibition of acid secretion in the treatment of gastrointestinal ulcers. Smooth muscle may also be affected. Some drugs in this class have strong effects in the central nervous system, but these actions are not well understood. (See all compounds classified as Histamine H2 Antagonists.)

4.2 ATC Code

A - Alimentary tract and metabolism

A02 - Drugs for acid related disorders

A02B - Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord)

A02BA - H2-receptor antagonists

A02BA08 - Lafutidine